News
The Commision and the Canadian Minister of Innovation, Science and Industry have signed the agreement yesterday of Canada's association to Pillar II of Horizon Europe. Canadian entities can now join and lead research consortia. They mentioned as crcucial areas oceans, health, raw materials, energy, bioeconomy, artificial intelligence, cybersecurity and digital infrastructure.
More details in this press release.
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
Are you planning to submit a proposal under the EDF-EDIP-USI-2026-LS-IRA-MAB call? (EDF Call for proposals for industrial reinforcement actions under the Ukraine Support Instrument)The European Commission has published a revised version of the call document, taking into account the possibility that additional funding may become available under...
Read moreThe new Digital Europe calls are expected to open in January 2027. Now is the time to look for your potential partners and form consortia.
Read moreThe 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...
Read moreESA Space Solutions has opened a call for proposals on space-enabled solutions for resilient electricity grids, in collaboration with ENTSO-E. The call supports proof-of-concept studies and pilot projects that address challenges in grid resilience and operational continuity.
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
